Llwytho...
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
In recent years the incretin therapies have provided a new treatment option for patients with type 2 diabetes mellitus (T2DM). The incretin therapies focus on the increasing levels of the two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). T...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Hindawi Publishing Corporation
2012
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3483791/ https://ncbi.nlm.nih.gov/pubmed/23125920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/381713 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|